Palvella Therapeutics (PVLA) versus Its Competitors Financial Comparison

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Palvella Therapeutics to related companies based on the strength of its analyst recommendations, earnings, risk, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Palvella Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-235.83%	-32.89%

Earnings & Valuation

This table compares Palvella Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.60
Palvella Therapeutics Competitors	$9.95 billion	$135.48 million	-7.85

Palvella Therapeutics’ rivals have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Palvella Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8167	21850	49740	1314	2.55

Palvella Therapeutics currently has a consensus target price of $40.33, suggesting a potential upside of 108.23%. As a group, “Pharmaceutical preparations” companies have a potential upside of 199.89%. Given Palvella Therapeutics’ rivals higher probable upside, analysts clearly believe Palvella Therapeutics has less favorable growth aspects than its rivals.

Risk and Volatility

Palvella Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ rivals have a beta of 3.64, meaning that their average share price is 264% more volatile than the S&P 500.

Insider and Institutional Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.4% of Palvella Therapeutics shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Palvella Therapeutics rivals beat Palvella Therapeutics on 8 of the 13 factors compared.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.